Terms: = Ovarian cancer AND ATIC, IMPCHASE, 471, ENSG00000138363, AICARFT, P31939, PURH AND Treatment
18 results:
1. Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer.
Barreto MCA; Treistman N; Cavalcante LBCP; Bulzico D; de Andrade FA; Corbo R; Alves Junior PAG; Vaisman F
Eur Thyroid J; 2024 Apr; 13(2):. PubMed ID: 38290210
[TBL] [Abstract] [Full Text] [Related]
2. Circulating small extracellular vesicles microRNAs plus CA-125 for treatment stratification in advanced ovarian cancer.
Zhou X; Liu M; Sun L; Cao Y; Tan S; Luo G; Liu T; Yao Y; Xiao W; Wan Z; Tang J
J Transl Med; 2023 Dec; 21(1):927. PubMed ID: 38129848
[TBL] [Abstract] [Full Text] [Related]
3. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract] [Full Text] [Related]
4. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Lee CK; Friedlander ML; Tjokrowidjaja A; Ledermann JA; Coleman RL; Mirza MR; Matulonis UA; Pujade-Lauraine E; Bloomfield R; Goble S; Wang P; Glasspool RM; Scott CL;
Cancer; 2021 Jul; 127(14):2432-2441. PubMed ID: 33740262
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
[TBL] [Abstract] [Full Text] [Related]
6. Feasibility of
Bunyaeva E; Kirillova A; Khabas G; Asaturova A; Mishieva N; Nazarenko T; Abubakirov A; Sukhikh G
Int J Gynecol Cancer; 2021 Mar; 31(3):475-479. PubMed ID: 33649016
[TBL] [Abstract] [Full Text] [Related]
7. Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.
Tewari KS; Sill MW; Coleman RL; Aghajanian C; Mannel R; DiSilvestro PA; Powell M; Randall LM; Farley J; Rubin SC; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):79-87. PubMed ID: 32723679
[TBL] [Abstract] [Full Text] [Related]
8. Incidence, risk factors, treatment, and survival of ovarian metastases of colorectal origin: a Dutch population-based study.
Bakkers C; van der Meer R; Roumen RM; Lurvink RJ; Lemmens VE; van Erning FN; de Hingh IH
Int J Colorectal Dis; 2020 Jun; 35(6):1035-1044. PubMed ID: 32157379
[TBL] [Abstract] [Full Text] [Related]
9. Effects of metastasectomy and other factors on survival of patients with ovarian metastases from gastric cancer: a systematic review and meta-analysis.
Zhang C; Hou W; Huang J; Yin S; Wang P; Zhang Z; Tan Y; Xu H
J Cell Biochem; 2019 Sep; 120(9):14486-14498. PubMed ID: 31050365
[TBL] [Abstract] [Full Text] [Related]
10. Significance of postmenopausal uterine leiomyomas: Focus on variants.
Oi Y; Katayama K; Hirata G; Ishidera Y; Yoshida H; Shigeta H
J Obstet Gynaecol Res; 2018 Aug; 44(8):1445-1450. PubMed ID: 29845685
[TBL] [Abstract] [Full Text] [Related]
11. OV21/PETROC: a randomized Gynecologic cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Provencher DM; Gallagher CJ; Parulekar WR; Ledermann JA; Armstrong DK; Brundage M; Gourley C; Romero I; Gonzalez-Martin A; Feeney M; Bessette P; Hall M; Weberpals JI; Hall G; Lau SK; Gauthier P; Fung-Kee-Fung M; Eisenhauer EA; Winch C; Tu D; MacKay HJ
Ann Oncol; 2018 Feb; 29(2):431-438. PubMed ID: 29186319
[TBL] [Abstract] [Full Text] [Related]
12. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract] [Full Text] [Related]
13. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
[TBL] [Abstract] [Full Text] [Related]
14. Unexpected ovarian malignancy found after laparoscopic surgery in patients with adnexal masses--a single institutional experience.
Saito S; Kajiyama H; Miwa Y; Mizuno M; Kikkawa F; Tanaka S; Okamoto T
Nagoya J Med Sci; 2014 Feb; 76(1-2):83-90. PubMed ID: 25129994
[TBL] [Abstract] [Full Text] [Related]
15. Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study.
Song T; Seong SJ; Bae DS; Suh DH; Kim DY; Lee KH; Lim MC; Lee TS
Gynecol Oncol; 2013 Dec; 131(3):624-8. PubMed ID: 24051220
[TBL] [Abstract] [Full Text] [Related]
16. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
Palmieri C; Gojis O; Rudraraju B; Stamp-Vincent C; Wilson D; Langdon S; Gourley C; Faratian D
Br J Cancer; 2013 May; 108(10):2039-44. PubMed ID: 23652306
[TBL] [Abstract] [Full Text] [Related]
17. Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and ovarian cancer Center (Italy).
Razzaboni E; Toss A; Cortesi L; Marchi I; Sebastiani F; De Matteis E; Federico M
Breast J; 2013; 19(1):10-21. PubMed ID: 23252601
[TBL] [Abstract] [Full Text] [Related]
18. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.
Bookman MA; McGuire WP; Kilpatrick D; Keenan E; Hogan WM; Johnson SW; O'Dwyer P; Rowinsky E; Gallion HH; Ozols RF
J Clin Oncol; 1996 Jun; 14(6):1895-902. PubMed ID: 8656258
[TBL] [Abstract] [Full Text] [Related]
